These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

107 related items for PubMed ID: 8947584

  • 1. Heterogenous effects of bryostatin on human myeloid leukemia clonogenicity: dose and time scheduling dependency.
    van der Hem KG, Schuurhuis GJ, Dräger AM, Odding JH, Huijgens PC.
    Leuk Res; 1996 Sep; 20(9):743-50. PubMed ID: 8947584
    [Abstract] [Full Text] [Related]

  • 2. Role of TNF alpha in bryostatin-induced inhibition of human hematopoiesis.
    Dräger AM, van der Hem KG, Zevenbergen A, Odding JH, Huijgens PC, Schuurhuis GJ.
    Leukemia; 1999 Jan; 13(1):62-9. PubMed ID: 10049062
    [Abstract] [Full Text] [Related]

  • 3. Effects of bryostatin-5 and hematopoietic growth factors on acute myeloid leukemia cell differentiation, proliferation, and primary plating efficiency.
    van der Hem KG, Dräger AM, Odding JH, Huijgens PC.
    Leuk Res; 1995 Sep; 19(9):651-7. PubMed ID: 7564476
    [Abstract] [Full Text] [Related]

  • 4. Differentiation and growth modulation of myeloid leukemia cells by the protein kinase C activating agent bryostatin-1.
    Steube KG, Drexler HG.
    Leuk Lymphoma; 1993 Jan; 9(1-2):141-8. PubMed ID: 8477194
    [Abstract] [Full Text] [Related]

  • 5. Bryostatin-5 stimulates normal human hematopoiesis and inhibits proliferation of HL60 leukemic cells.
    van der Hem KG, Dräger AM, Odding JH, Langenhuijsen MM, Huijgens PC.
    Leuk Res; 1995 Jan; 19(1):7-13. PubMed ID: 7837820
    [Abstract] [Full Text] [Related]

  • 6. Effect of the protein kinase C activating agent bryostatin 1 on the clonogenic response of leukemic blast progenitors to recombinant granulocyte-macrophage colony-stimulating factor.
    Grant S, Pettit GR, Howe C, McCrady C.
    Leukemia; 1991 May; 5(5):392-8. PubMed ID: 2033960
    [Abstract] [Full Text] [Related]

  • 7. Effect of a combined exposure to cytosine arabinoside, bryostatin 1, and recombinant granulocyte-macrophage colony-stimulating factor on the clonogenic growth in vitro of normal and leukemic human hematopoietic progenitor cells.
    Grant S, Traylor R, Bhalla K, McCrady C, Pettit GR.
    Leukemia; 1992 May; 6(5):432-9. PubMed ID: 1593908
    [Abstract] [Full Text] [Related]

  • 8. Bryostatin 1, a unique biologic response modifier: anti-leukemic activity in vitro.
    Jones RJ, Sharkis SJ, Miller CB, Rowinsky EK, Burke PJ, May WS.
    Blood; 1990 Mar 15; 75(6):1319-23. PubMed ID: 2310830
    [Abstract] [Full Text] [Related]

  • 9. Bryostatin 1 acts synergistically with interleukin-1 alpha to induce secretion of G-CSF and other cytokines from marrow stromal cells.
    Lilly M, Vo K, Le T, Takahashi G.
    Exp Hematol; 1996 Apr 15; 24(5):613-21. PubMed ID: 8605966
    [Abstract] [Full Text] [Related]

  • 10. Sequential treatment of human chronic lymphocytic leukemia with bryostatin 1 followed by 2-chlorodeoxyadenosine: preclinical studies.
    Mohammad RM, Katato K, Almatchy VP, Wall N, Liu KZ, Schultz CP, Mantsch HH, Varterasian M, al-Katib AM.
    Clin Cancer Res; 1998 Feb 15; 4(2):445-53. PubMed ID: 9516935
    [Abstract] [Full Text] [Related]

  • 11. Treatment of a de novo fludarabine resistant-CLL xenograft model with bryostatin 1 followed by fludarabine.
    Mohammad RM, Limvarapuss C, Hamdy N, Dutcher BS, Beck FW, Wall NR, Al-Katib AM.
    Int J Oncol; 1999 May 15; 14(5):945-50. PubMed ID: 10200346
    [Abstract] [Full Text] [Related]

  • 12. Bryostatin 1-induced modulation of the acute lymphoblastic leukemia cell line Reh.
    al-Katib A, Mohammad RM, Khan K, Dan ME, Pettit GR, Sensenbrenner LL.
    J Immunother Emphasis Tumor Immunol; 1993 Jul 15; 14(1):33-42. PubMed ID: 8399068
    [Abstract] [Full Text] [Related]

  • 13. Effects of bryostatin 1 and other pharmacological activators of protein kinase C on 1-[beta-D-arabinofuranosyl]cytosine-induced apoptosis in HL-60 human promyelocytic leukemia cells.
    Jarvis WD, Povirk LF, Turner AJ, Traylor RS, Gewirtz DA, Pettit GR, Grant S.
    Biochem Pharmacol; 1994 Mar 02; 47(5):839-52. PubMed ID: 8135859
    [Abstract] [Full Text] [Related]

  • 14. Activation of T-cells by bryostatins: induction of the IL-2 receptor gene transcription and down-modulation of surface receptors.
    Esa AH, Boto WO, Adler WH, May WS, Hess AD.
    Int J Immunopharmacol; 1990 Mar 02; 12(5):481-90. PubMed ID: 2210911
    [Abstract] [Full Text] [Related]

  • 15. Phase I trial and correlative laboratory studies of bryostatin 1 (NSC 339555) and high-dose 1-B-D-arabinofuranosylcytosine in patients with refractory acute leukemia.
    Cragg LH, Andreeff M, Feldman E, Roberts J, Murgo A, Winning M, Tombes MB, Roboz G, Kramer L, Grant S.
    Clin Cancer Res; 2002 Jul 02; 8(7):2123-33. PubMed ID: 12114412
    [Abstract] [Full Text] [Related]

  • 16. Inhibition of phorbol ester-induced T cell proliferation by bryostatin is associated with rapid degradation of protein kinase C.
    Isakov N, Galron D, Mustelin T, Pettit GR, Altman A.
    J Immunol; 1993 Feb 15; 150(4):1195-204. PubMed ID: 8432975
    [Abstract] [Full Text] [Related]

  • 17. Differentiation and growth modulation of chronic myelogenous leukemia cells by bryostatin.
    Lilly M, Tompkins C, Brown C, Pettit G, Kraft A.
    Cancer Res; 1990 Sep 01; 50(17):5520-5. PubMed ID: 2386956
    [Abstract] [Full Text] [Related]

  • 18. The effect of bryostatin on protein kinase C-regulated functions in human T lymphocytes and epidermal keratinocytes.
    Galron D, Tamir A, Gelkop S, Grossman N, Isakov N.
    Immunol Lett; 1993 Dec 01; 39(1):17-22. PubMed ID: 8144186
    [Abstract] [Full Text] [Related]

  • 19. Primary acute myeloid leukaemia blasts resistant to cytokine-induced differentiation to dendritic-like leukaemia cells can be forced to differentiate by the addition of bryostatin-1.
    Roddie PH, Horton Y, Turner ML.
    Leukemia; 2002 Jan 01; 16(1):84-93. PubMed ID: 11840267
    [Abstract] [Full Text] [Related]

  • 20. Different biological effects of the two protein kinase C activators bryostatin-1 and TPA on human carcinoma cell lines.
    Steube KG, Grunicke D, Drexler HG.
    Invest New Drugs; 1994 Jan 01; 12(1):15-23. PubMed ID: 7960600
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.